Want to see COR full AI Analyst Report?
Revenue by Segment
Shows how sales are split across the company’s business lines (e.g., distribution versus higher-margin services), revealing which units drive growth and where the company is most exposed to pricing pressure, customer concentration, or regional risk.U.S. Healthcare remains the revenue engine but is showing near‑term top‑line pressure from WAC price cuts, account losses and faster branded mail‑order conversions; that weakness is being offset by accelerating International and a newly reported Other bucket (post‑OneOncology) that carry better margins. Management raised operating income and EPS guidance despite lowering revenue growth, so the story is margin and cash‑flow driven rather than pure top‑line expansion. The large rise in intersegment eliminations flags acquisition consolidation and makes segment comparability noisier — focus on margins and FCF.
Date | Other | Intersegment Eliminations | U.S. Healthcare Solutions | International Healthcare Solutions |
|---|---|---|---|---|
Jun 30, 2026 | $2.25B | -$39.71M | $74.86B | $7.68B |
Mar 31, 2026 | $2.06B | -$30.48M | $68.77B | $7.57B |
Dec 31, 2025 | $2.13B | -$32.73M | $76.21B | $7.62B |
Sep 30, 2025 | $0.00 | -$4.93M | $75.79B | $7.94B |
Jun 30, 2025 | $0.00 | -$3.47M | $72.88B | $7.79B |
Mar 31, 2025 | $0.00 | -$3.71M | $68.28B | $7.17B |
Dec 31, 2024 | $0.00 | -$3.41M | $74.03B | $7.46B |
Sep 30, 2024 | $0.00 | -$3.08M | $71.67B | $7.38B |
Jun 30, 2024 | $0.00 | -$2.12M | $67.19B | $7.05B |
Mar 31, 2024 | $0.00 | -$1.98M | $61.29B | $7.12B |